ASCO 2019 No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases

ASCO 2019: No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases

09:23 EDT 4 Jun 2019 | ecancermedicalscience

he E2810 research study was conducted to determine whether taking the oral drug pazopanib following surgery to remove further metastases in patients with advanced renal cell carcinoma would improve their disease-free survival. The trial was designed and...

More From BioPortfolio on "ASCO 2019: No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases"